← Back to patent-cliff list
EVO-756
Tier C — Watch / tradeEVO-756
Dermira Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Mas-related G-protein coupled receptor member X2
Indications (approved)：Migraine, Atopic dermatitis, Chronic urticaria, Pruritus, 间质性膀胱炎
Regional status
US
Phase II
2024-08-14
EU
-
China
Phase I
2026-05-28
Japan
Phase II
2025-03-20
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of EVO-756?
Approved indications include: Migraine, Atopic dermatitis, Chronic urticaria, Pruritus, 间质性膀胱炎.
When does the EVO-756 patent expire?
No public expiry year is available for EVO-756 yet; this page updates once verified.
How do I get a quote for EVO-756 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01